[TITLE]MetLife Investment Management LLC Cuts Stock Holdings in Acadia Healthcare Company, Inc. $ACHC:
[TEXT]
MetLife Investment Management LLC lowered its stake in shares of Acadia Healthcare Company, Inc. (NASDAQ:ACHC – Free Report) by 1.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 51,545 shares of the company’s stock after selling 781 shares during the period. MetLife Investment Management LLC owned approximately 0.06% of Acadia Healthcare worth $1,563,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Caitong International Asset Management Co. Ltd raised its stake in shares of Acadia Healthcare by 11,218.2% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,245 shares of the company’s stock valued at $38,000 after acquiring an additional 1,234 shares during the period. UMB Bank n.a. raised its stake in shares of Acadia Healthcare by 149.5% in the 1st quarter. UMB Bank n.a. now owns 1,260 shares of the company’s stock valued at $38,000 after acquiring an additional 755 shares during the period. State of Wyoming purchased a new position in shares of Acadia Healthcare in the 4th quarter valued at $56,000. Covestor Ltd raised its stake in shares of Acadia Healthcare by 56.0% in the 1st quarter. Covestor Ltd now owns 2,262 shares of the company’s stock valued at $69,000 after acquiring an additional 812 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of Acadia Healthcare by 143.8% in the 1st quarter. GAMMA Investing LLC now owns 5,812 shares of the company’s stock valued at $176,000 after acquiring an additional 3,428 shares during the period.

Get Acadia Healthcare alerts:

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ACHC shares. Raymond James Financial reissued an “outperform” rating and issued a $26.00 target price (down previously from $40.00) on shares of Acadia Healthcare in a research note on Thursday, August 14th. Wall Street Zen raised shares of Acadia Healthcare from a “sell” rating to a “hold” rating in a research note on Sunday, August 3rd. Mizuho lowered their price target on shares of Acadia Healthcare from $32.00 to $22.00 and set a “neutral” rating for the company in a report on Wednesday, August 13th. Guggenheim lowered their price target on shares of Acadia Healthcare from $36.00 to $29.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Finally, UBS Group lowered their price target on shares of Acadia Healthcare from $45.00 to $31.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Nine research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.77.

Acadia Healthcare Price Performance

ACHC opened at $23.33 on Thursday. The company has a fifty day simple moving average of $22.14 and a 200 day simple moving average of $25.17. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of 15.45, a PEG ratio of 4.52 and a beta of 0.89. Acadia Healthcare Company, Inc. has a twelve month low of $17.13 and a twelve month high of $79.82. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.73.

Acadia Healthcare (NASDAQ:ACHC – Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.12. The company had revenue of $869.23 million during the quarter, compared to analyst estimates of $839.59 million. Acadia Healthcare had a net margin of 4.31% and a return on equity of 8.34%. The firm’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same period last year, the business earned $0.91 EPS. Acadia Healthcare has set its FY 2025 guidance at 2.450-2.65 EPS. Equities research analysts expect that Acadia Healthcare Company, Inc. will post 3.38 EPS for the current fiscal year.

Acadia Healthcare Profile

(Free Report)

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.

See Also

Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/04/metlife-investment-management-llc-cuts-stock-holdings-in-acadia-healthcare-company-inc-achc/


[TITLE]Northern Trust Corp Decreases Stake in National HealthCare Co. $NHC:
[TEXT]
Northern Trust Corp lessened its position in shares of National HealthCare Co. (NYSE:NHC – Free Report) by 3.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 186,217 shares of the company’s stock after selling 7,575 shares during the quarter. Northern Trust Corp’s holdings in National HealthCare were worth $17,281,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of NHC. State of Wyoming bought a new position in shares of National HealthCare during the 4th quarter valued at approximately $93,000. Hohimer Wealth Management LLC raised its stake in National HealthCare by 6.9% during the first quarter. Hohimer Wealth Management LLC now owns 2,479 shares of the company’s stock valued at $230,000 after purchasing an additional 160 shares in the last quarter. Algert Global LLC bought a new position in National HealthCare during the first quarter valued at $314,000. XTX Topco Ltd lifted its position in National HealthCare by 51.3% during the first quarter. XTX Topco Ltd now owns 4,030 shares of the company’s stock valued at $374,000 after purchasing an additional 1,367 shares during the last quarter. Finally, ProShare Advisors LLC grew its stake in shares of National HealthCare by 45.2% in the 4th quarter. ProShare Advisors LLC now owns 3,761 shares of the company’s stock worth $405,000 after buying an additional 1,170 shares in the last quarter. 56.44% of the stock is owned by hedge funds and other institutional investors.

Get National HealthCare alerts:

National HealthCare Stock Performance

Shares of National HealthCare stock opened at $112.53 on Wednesday. The company has a market capitalization of $1.74 billion, a PE ratio of 14.10 and a beta of 0.57. National HealthCare Co. has a 52 week low of $89.14 and a 52 week high of $136.88. The stock’s fifty day moving average is $103.92 and its two-hundred day moving average is $99.66. The company has a quick ratio of 1.77, a current ratio of 1.80 and a debt-to-equity ratio of 0.14.

National HealthCare Announces Dividend

Wall Street Analysts Forecast Growth

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.64 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $2.56 dividend on an annualized basis and a dividend yield of 2.3%. National HealthCare’s dividend payout ratio is presently 38.15%.

Separately, Wall Street Zen upgraded shares of National HealthCare from a “buy” rating to a “strong-buy” rating in a research report on Monday, May 12th.

Check Out Our Latest Stock Analysis on National HealthCare

About National HealthCare

(Free Report)

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. Its skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities.

Read More

Want to see what other hedge funds are holding NHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for National HealthCare Co. (NYSE:NHC – Free Report).

Receive News & Ratings for National HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/03/northern-trust-corp-decreases-stake-in-national-healthcare-co-nhc/


[TITLE]Nuveen LLC Invests $787,000 in Viemed Healthcare, Inc. $VMD:
[TEXT]
Nuveen LLC acquired a new position in Viemed Healthcare, Inc. (NASDAQ:VMD – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 108,112 shares of the company’s stock, valued at approximately $787,000.

Several other institutional investors have also made changes to their positions in the company. R Squared Ltd increased its position in shares of Viemed Healthcare by 276.5% in the first quarter. R Squared Ltd now owns 19,110 shares of the company’s stock worth $139,000 after acquiring an additional 14,034 shares in the last quarter. GSA Capital Partners LLP increased its position in shares of Viemed Healthcare by 497.7% in the first quarter. GSA Capital Partners LLP now owns 149,791 shares of the company’s stock worth $1,090,000 after acquiring an additional 124,731 shares in the last quarter. Corton Capital Inc. increased its position in shares of Viemed Healthcare by 45.4% in the first quarter. Corton Capital Inc. now owns 14,842 shares of the company’s stock worth $108,000 after acquiring an additional 4,634 shares in the last quarter. BCM Advisors LLC increased its position in shares of Viemed Healthcare by 10.6% in the first quarter. BCM Advisors LLC now owns 23,520 shares of the company’s stock worth $173,000 after acquiring an additional 2,250 shares in the last quarter. Finally, Segall Bryant & Hamill LLC increased its position in shares of Viemed Healthcare by 252.1% in the first quarter. Segall Bryant & Hamill LLC now owns 130,229 shares of the company’s stock worth $948,000 after acquiring an additional 93,242 shares in the last quarter. 74.24% of the stock is owned by hedge funds and other institutional investors.

Get Viemed Healthcare alerts:

Insider Buying and Selling at Viemed Healthcare

In other news, President Michael Moore sold 50,090 shares of Viemed Healthcare stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $7.33, for a total value of $367,159.70. Following the transaction, the president owned 126,343 shares of the company’s stock, valued at $926,094.19. This trade represents a 28.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Nitin Kaushal sold 34,100 shares of Viemed Healthcare stock in a transaction that occurred on Friday, June 27th. The shares were sold at an average price of $7.01, for a total transaction of $239,041.00. Following the completion of the transaction, the director directly owned 126,843 shares in the company, valued at approximately $889,169.43. This represents a 21.19% decrease in their position. The disclosure for this sale can be found here. Insiders sold 97,922 shares of company stock worth $703,886 over the last ninety days. 20.00% of the stock is currently owned by insiders.

Viemed Healthcare Stock Performance

Viemed Healthcare stock opened at $6.81 on Wednesday. The firm’s 50 day simple moving average is $6.81 and its 200-day simple moving average is $6.96. The company has a market cap of $264.16 million, a P/E ratio of 20.03 and a beta of 1.38. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.48 and a quick ratio of 1.37. Viemed Healthcare, Inc. has a fifty-two week low of $5.93 and a fifty-two week high of $9.81.

Viemed Healthcare (NASDAQ:VMD – Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.08 EPS for the quarter, hitting the consensus estimate of $0.08. The business had revenue of $63.06 million during the quarter, compared to analysts’ expectations of $63.50 million. Viemed Healthcare had a net margin of 5.80% and a return on equity of 10.38%.

Viemed Healthcare Company Profile

(Free Report)

Viemed Healthcare, Inc, together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.

See Also

Want to see what other hedge funds are holding VMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viemed Healthcare, Inc. (NASDAQ:VMD – Free Report).

Receive News & Ratings for Viemed Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viemed Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/03/nuveen-llc-invests-787000-in-viemed-healthcare-inc-vmd/


[TITLE]MetLife Investment Management LLC Decreases Stock Holdings in American Healthcare REIT, Inc. $AHR:
[TEXT]
MetLife Investment Management LLC trimmed its holdings in American Healthcare REIT, Inc. (NYSE:AHR – Free Report) by 1.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,449 shares of the company’s stock after selling 1,507 shares during the quarter. MetLife Investment Management LLC’s holdings in American Healthcare REIT were worth $2,862,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Wolff Wiese Magana LLC purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $25,000. MassMutual Private Wealth & Trust FSB raised its position in shares of American Healthcare REIT by 189.0% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 968 shares of the company’s stock valued at $29,000 after buying an additional 633 shares during the period. Spirit of America Management Corp NY purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $30,000. Avalon Trust Co purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $36,000. Finally, Continuum Advisory LLC purchased a new stake in shares of American Healthcare REIT during the 1st quarter valued at approximately $37,000. Hedge funds and other institutional investors own 16.68% of the company’s stock.

Get American Healthcare REIT alerts:

Insider Buying and Selling at American Healthcare REIT

In other news, CIO Stefan K.L. Oh sold 3,860 shares of the company’s stock in a transaction on Monday, June 30th. The stock was sold at an average price of $36.10, for a total transaction of $139,346.00. Following the sale, the executive owned 95,671 shares of the company’s stock, valued at approximately $3,453,723.10. This represents a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.00% of the company’s stock.

American Healthcare REIT Stock Performance

NYSE:AHR opened at $42.79 on Monday. American Healthcare REIT, Inc. has a 52 week low of $20.15 and a 52 week high of $43.14. The company has a fifty day simple moving average of $38.75 and a two-hundred day simple moving average of $34.08. The company has a quick ratio of 0.48, a current ratio of 0.48 and a debt-to-equity ratio of 0.41. The company has a market cap of $7.21 billion, a price-to-earnings ratio of -194.48, a price-to-earnings-growth ratio of 2.19 and a beta of 1.09.

American Healthcare REIT (NYSE:AHR – Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.40 by $0.02. American Healthcare REIT had a negative return on equity of 1.43% and a negative net margin of 1.56%.The business had revenue of $542.50 million for the quarter, compared to analyst estimates of $539.49 million. During the same quarter in the prior year, the company earned $0.33 earnings per share. The company’s revenue was up 7.5% on a year-over-year basis. American Healthcare REIT has set its FY 2025 guidance at 1.640-1.680 EPS. As a group, equities analysts anticipate that American Healthcare REIT, Inc. will post 1.41 earnings per share for the current fiscal year.

American Healthcare REIT Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 18th. Stockholders of record on Monday, June 30th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Monday, June 30th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.3%. American Healthcare REIT’s dividend payout ratio is currently -454.55%.

Wall Street Analyst Weigh In

Several research firms have recently commented on AHR. Morgan Stanley lifted their price target on shares of American Healthcare REIT from $37.00 to $45.00 and gave the company an “overweight” rating in a research report on Tuesday, May 20th. JMP Securities lifted their price target on shares of American Healthcare REIT from $40.00 to $45.00 and gave the company a “market outperform” rating in a research report on Monday, August 11th. Robert W. Baird started coverage on shares of American Healthcare REIT in a research report on Friday, July 18th. They set an “outperform” rating and a $41.00 price target on the stock. KeyCorp boosted their target price on American Healthcare REIT from $34.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, June 11th. Finally, Baird R W raised American Healthcare REIT to a “strong-buy” rating in a research report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the stock. According to data from MarketBeat.com, American Healthcare REIT presently has a consensus rating of “Buy” and a consensus price target of $41.89.

Check Out Our Latest Stock Report on AHR

American Healthcare REIT Company Profile

(Free Report)

Formed by the successful merger of Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, as well as the acquisition of the business and operations of American Healthcare Investors, American Healthcare REIT is one of the larger healthcare-focused real estate investment trusts globally with assets totaling approximately $4.2 billion in gross investment value.

Further Reading

Want to see what other hedge funds are holding AHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for American Healthcare REIT, Inc. (NYSE:AHR – Free Report).

Receive News & Ratings for American Healthcare REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Healthcare REIT and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/01/metlife-investment-management-llc-decreases-stock-holdings-in-american-healthcare-reit-inc-ahr/

================================================================================

[TITLE]Medical Properties’ (MPW) Lease Deal with NOR Healthcare Supports Cash Flow Visibility:
[TEXT]
Medical Properties Trust Inc. (NYSE:MPW) is one of the most shorted stocks right now. On August 28, Medical Properties Trust Inc. (NYSE:MPW) announced a new lease agreement with NOR Healthcare Systems following its winning bid for Prospect Medical Group’s California operations. The deal encompasses six facilities under a master lease with an initial annualized rent of $45 million, which is broadly in line with Prospect’s previously scheduled 2025 obligations. Rent will be partially deferred during the first year, with repayment spread over the entire lease term.

Medical Properties’ (MPW) Lease Deal with NOR Healthcare Supports Cash Flow Visibility

Medical Properties Trust Inc. (NYSE:MPW) has also committed up to $60 million in seismic upgrades, which will be added to the lease base and generate additional rent at standard yields.

Management highlighted that the arrangement strengthens cash flow visibility, contributing to the company’s target of exceeding $1 billion in pro rata annualized rent by the end of 2026. They also believe that strong interest from multiple operators in acquiring these assets underscores their operating resilience and history of profitability.

Medical Properties Trust Inc. (NYSE:MPW) is a real estate investment trust specializing in owning and leasing hospitals and healthcare facilities across the U.S. and internationally.

While we acknowledge the potential of MPW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Stocks for a 20 Year Long-Term Stock Portfolio and 12 Overlooked Large-Cap Stocks with Low Multiples.

Disclosure: None. This article is originally published at Insider Monkey.
[Source link]: https://finance.yahoo.com/news/medical-properties-mpw-lease-deal-171407620.html


[TITLE]Saudi Arabia Clinical Nutrition Market Analysis Report 2025-2030 | Lifestyle Shifts, Health Consciousness, and Enhanced Healthcare Access Bolster Growth:
[TEXT]
Dublin, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Clinical Nutrition Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to ResearchAndMarkets.com's offering.

The Saudi Arabia Clinical Nutrition Market was valued at USD 0.96 Billion in 2024, and is expected to reach USD 1.53 Billion by 2030, rising at a CAGR of 8.08%

This involves evaluating dietary habits, analyzing biochemical markers, considering medical history, and assessing anthropometric measurements (such as height, weight, and body composition). Based on the nutritional assessment, healthcare professionals, such as registered dietitians or nutritionists, provide personalized dietary counseling.

This includes recommendations for dietary modifications, nutrient supplementation, and lifestyle changes tailored to the individual's specific health needs and goals. Clinical nutrition often involves the application of medical nutrition therapy, which is the use of specific nutrition interventions to treat or manage medical conditions. This may include creating therapeutic diets for conditions such as diabetes, cardiovascular diseases, gastrointestinal disorders, and malnutrition.

Advancements in technology, such as personalized nutrition plans and digital tools for monitoring nutritional intake, can drive innovation and market growth in the clinical nutrition sector. A focus on maternal and child health, along with an emphasis on early childhood nutrition, can drive demand for pediatric clinical nutrition products. Shifts in lifestyle patterns, including dietary habits and a growing interest in fitness and wellness, can contribute to the demand for specialized clinical nutrition products. Increasing disposable income levels in the population can lead to higher spending on healthcare and wellness products, including clinical nutrition. Improvements in healthcare infrastructure, including hospitals and clinics, can enhance access to clinical nutrition products and services.

Key Market Drivers

Technological Innovations

Mobile apps and web platforms designed to monitor and track dietary habits, nutritional intake, and overall health. These platforms may offer personalized recommendations, meal planning, and tools for individuals to manage their nutrition more effectively. Telehealth technologies allow healthcare professionals to remotely monitor patients' nutritional status, provide virtual consultations, and offer dietary guidance. This is especially valuable for patients who may have difficulty accessing in-person care.

Advances in genetics and personalized medicine have led to the emergence of nutrigenomics, which involves studying how an individual's genetic makeup influences their response to nutrients. This can guide personalized dietary recommendations based on genetic factors. Internet of Things (IoT) devices and smart kitchen appliances can assist individuals in preparing and consuming nutritionally balanced meals. These devices may sync with mobile apps to track dietary choices and provide insights into nutritional content.

Wearables, such as fitness trackers and smartwatches, can monitor physical activity, sleep patterns, and sometimes even nutritional intake. This data can be used to assess overall health and tailor dietary recommendations. Artificial Intelligence (AI) and Machine Learning (ML) algorithms are being utilized to analyze vast datasets related to nutrition, metabolism, and health outcomes.

This can lead to more precise personalized nutrition recommendations based on individual health parameters. Integration of nutrition-related information into electronic health records allows for a more comprehensive view of a patient's health history, facilitating better-informed decisions by healthcare professionals. Customized nutritional supplements and enteral feeding solutions can be created using 3D printing technology. This enables healthcare providers to tailor nutritional interventions to specific patient needs.

Virtual Reality (VR) and Augmented Reality (AR) applications are being explored for nutrition education and therapy. These technologies can create immersive experiences to teach patients
[Source link]: https://www.globenewswire.com/news-release/2025/09/04/3144784/28124/en/Saudi-Arabia-Clinical-Nutrition-Market-Analysis-Report-2025-2030-Lifestyle-Shifts-Health-Consciousness-and-Enhanced-Healthcare-Access-Bolster-Growth.html


[TITLE]MetLife Investment Management LLC Cuts Stock Holdings in Acadia Healthcare Company, Inc. $ACHC:
[TEXT]
MetLife Investment Management LLC lowered its stake in shares of Acadia Healthcare Company, Inc. (NASDAQ:ACHC – Free Report) by 1.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 51,545 shares of the company’s stock after selling 781 shares during the period. MetLife Investment Management LLC owned approximately 0.06% of Acadia Healthcare worth $1,563,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Caitong International Asset Management Co. Ltd raised its stake in shares of Acadia Healthcare by 11,218.2% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,245 shares of the company’s stock valued at $38,000 after acquiring an additional 1,234 shares during the period. UMB Bank n.a. raised its stake in shares of Acadia Healthcare by 149.5% in the 1st quarter. UMB Bank n.a. now owns 1,260 shares of the company’s stock valued at $38,000 after acquiring an additional 755 shares during the period. State of Wyoming purchased a new position in shares of Acadia Healthcare in the 4th quarter valued at $56,000. Covestor Ltd raised its stake in shares of Acadia Healthcare by 56.0% in the 1st quarter. Covestor Ltd now owns 2,262 shares of the company’s stock valued at $69,000 after acquiring an additional 812 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of Acadia Healthcare by 143.8% in the 1st quarter. GAMMA Investing LLC now owns 5,812 shares of the company’s stock valued at $176,000 after acquiring an additional 3,428 shares during the period.

Get Acadia Healthcare alerts:

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ACHC shares. Raymond James Financial reissued an “outperform” rating and issued a $26.00 target price (down previously from $40.00) on shares of Acadia Healthcare in a research note on Thursday, August 14th. Wall Street Zen raised shares of Acadia Healthcare from a “sell” rating to a “hold” rating in a research note on Sunday, August 3rd. Mizuho lowered their price target on shares of Acadia Healthcare from $32.00 to $22.00 and set a “neutral” rating for the company in a report on Wednesday, August 13th. Guggenheim lowered their price target on shares of Acadia Healthcare from $36.00 to $29.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Finally, UBS Group lowered their price target on shares of Acadia Healthcare from $45.00 to $31.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Nine research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.77.

Acadia Healthcare Price Performance

ACHC opened at $23.33 on Thursday. The company has a fifty day simple moving average of $22.14 and a 200 day simple moving average of $25.17. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of 15.45, a PEG ratio of 4.52 and a beta of 0.89. Acadia Healthcare Company, Inc. has a twelve month low of $17.13 and a twelve month high of $79.82. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.73.

Acadia Healthcare (NASDAQ:ACHC – Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.12. The company had revenue of $869.23 million during the quarter, compared to analyst estimates of $839.59 million. Acadia Healthcare had a net margin of 4.31% and a return on equity of 8.34%. The firm’s revenue for the quarter was up 9.2% compared to the same quarter last year. During the same period last year, the business earned $0.91 EPS. Acadia Healthcare has set its FY 2025 guidance at 2.450-2.65 EPS. Equities research analysts expect that Acadia Healthcare Company, Inc. will post 3.38 EPS for the current fiscal year.

Acadia Healthcare Profile

(Free Report)

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.

See Also

Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/04/metlife-investment-management-llc-cuts-stock-holdings-in-acadia-healthcare-company-inc-achc/


[TITLE]Questex’s Fierce Pharma, Fierce Biotech and Fierce Healthcare Unveil the 2025 Fierce 50:
[TEXT]
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Questex’s Fierce Pharma, Fierce Biotech and Fierce Healthcare today unveiled the 2025 Fierce 50—a project that highlights the individuals and organizations driving meaningful change across the healthcare, pharma and biotech industries.

The Fierce 50 honors innovators and leaders who are breaking new ground in research, technology, equity and care delivery. From launching first-in-class therapies and advancing AI in clinical workflows to reimagining healthcare access and harnessing data for smarter public health interventions, this year’s honorees are reshaping what’s possible. They’re playing a pivotal role in defining the future of health. The 50 honorees—spanning major pharmaceutical companies, startups, public health leaders and grassroots changemakers—are recognized in one of five categories: Innovation, Social Impact, Breakthrough, Health Equity and Leadership.

Click here to see the 2025 Fierce 50 honorees.

Ayla Ellison, Editor-in-Chief of Fierce Life Sciences and Healthcare, said, "The Fierce 50 of 2025 is
[Source link]: https://www.globenewswire.com/news-release/2025/09/02/3142999/0/en/Questex-s-Fierce-Pharma-Fierce-Biotech-and-Fierce-Healthcare-Unveil-the-2025-Fierce-50.html

================================================================================

[TITLE]NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a:
[TEXT]
WILMINGTON, Del., Sept. 03, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, today announced that Jonathan Javitt, M.D., M.P.H., Chairman and Chief Executive Officer of NRx Pharmaceuticals, will participate in a fireside chat at H.C. Wainwright’s 27th Annual Global Investment Conference on Monday, September 8, 2025, from 4:30 to 5:00 PM ET.

A webcast of the fireside chat will be available on the Events page of the Investors section of the Company’s website at https://ir.nrxpharma.com/events. A replay of the webcast will be available two hours after the event and will be accessible for 30 days following the event.

Management will also be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the NRx Pharmaceuticals management team should contact their H.C. Wainwright representative or Brian Korb at astr Partners, brian.korb@astrpartners.com.
[Source link]: https://www.globenewswire.com/news-release/2025/09/03/3143574/0/en/NRx-Pharmaceuticals-NASDAQ-NRXP-to-Participate-in-a-Fireside-Chat-at-H-C-Wainwright-s-27th-Annual-Global-Investment-Conference-on-Monday-September-8th.html


[TITLE]60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference:
[TEXT]
WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today the webcast link and change of date for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York City, to Tuesday, September 9, 3:30 PM Eastern Time.

Dr. Geoff Dow, 60 Degrees Pharma CEO, will present live and management will conduct one-on-one meetings during the conference.

Event: H.C. Wainwright 27th Annual Global Investment Conference

Date: September 9, 2025

Time: 3:30 PM ET

Location: Lotte New York Palace Hotel

Webcast: Register
[Source link]: https://www.globenewswire.com/news-release/2025/09/03/3143571/0/en/60-Degrees-Pharmaceuticals-Live-Webcast-Link-and-New-Date-for-Presentation-at-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html


[TITLE]PharmaCyte Biotech increases stake in TNF Pharmaceuticals by $3M PMCB;TNFA:
[TEXT]
Proprietary deal commentary available to members only.
[Source link]: https://thefly.com/permalinks/entry.php/id4191501/PMCB;TNFA-PharmaCyte-Biotech-increases-stake-in-TNF-Pharmaceuticals-by-M


[TITLE]Avadel Pharmaceuticals PLC. $AVDL Shares Bought by Charles Schwab Investment Management Inc.:
[TEXT]
Charles Schwab Investment Management Inc. increased its stake in Avadel Pharmaceuticals PLC. (NASDAQ:AVDL – Free Report) by 1.6% in the first quarter, Holdings Channel.com reports. The institutional investor owned 226,439 shares of the company’s stock after purchasing an additional 3,641 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Avadel Pharmaceuticals were worth $1,773,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of AVDL. Invesco Ltd. boosted its stake in shares of Avadel Pharmaceuticals by 2.3% in the fourth quarter. Invesco Ltd. now owns 52,142 shares of the company’s stock valued at $548,000 after purchasing an additional 1,177 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Avadel Pharmaceuticals by 3.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 52,594 shares of the company’s stock worth $553,000 after buying an additional 1,882 shares in the last quarter. Rhumbline Advisers lifted its holdings in Avadel Pharmaceuticals by 2.3% in the 1st quarter. Rhumbline Advisers now owns 127,027 shares of the company’s stock worth $995,000 after buying an additional 2,890 shares in the last quarter. MetLife Investment Management LLC boosted its position in Avadel Pharmaceuticals by 6.1% in the 4th quarter. MetLife Investment Management LLC now owns 57,068 shares of the company’s stock valued at $600,000 after buying an additional 3,271 shares during the last quarter. Finally, Edge Wealth Management LLC grew its stake in shares of Avadel Pharmaceuticals by 25.0% during the first quarter. Edge Wealth Management LLC now owns 25,000 shares of the company’s stock valued at $196,000 after acquiring an additional 5,000 shares in the last quarter. 69.19% of the stock is currently owned by hedge funds and other institutional investors.

Get Avadel Pharmaceuticals alerts:

Avadel Pharmaceuticals Trading Up 1.0%

Shares of NASDAQ AVDL opened at $14.76 on Monday. Avadel Pharmaceuticals PLC. has a twelve month low of $6.38 and a twelve month high of $16.66. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -492.00 and a beta of 1.57. The business has a 50 day simple moving average of $11.44 and a 200-day simple moving average of $9.53.

Analyst Upgrades and Downgrades

Avadel Pharmaceuticals ( NASDAQ:AVDL Get Free Report ) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.08. The firm had revenue of $68.13 million for the quarter, compared to analysts’ expectations of $60.28 million. Avadel Pharmaceuticals had a negative return on equity of 3.73% and a negative net margin of 1.32%.The firm’s revenue for the quarter was up 64.1% on a year-over-year basis. During the same period last year, the business posted ($0.14) earnings per share. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Avadel Pharmaceuticals PLC. will post -0.51 earnings per share for the current year.

Several research analysts recently commented on the company. Wall Street Zen upgraded Avadel Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Zacks Research upgraded Avadel Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $24.00 target price (up from $22.00) on shares of Avadel Pharmaceuticals in a research report on Friday, August 8th. Needham & Company LLC reissued a “buy” rating and set a $19.00 price target on shares of Avadel Pharmaceuticals in a research report on Thursday, May 8th. Finally, UBS Group lifted their price target on shares of Avadel Pharmaceuticals from $13.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, August 21st. One investment analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $19.67.

View Our Latest Stock Report on AVDL

About Avadel Pharmaceuticals

(Free Report)

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

Further Reading

Want to see what other hedge funds are holding AVDL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avadel Pharmaceuticals PLC. (NASDAQ:AVDL – Free Report).

Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/01/avadel-pharmaceuticals-plc-avdl-shares-bought-by-charles-schwab-investment-management-inc/

================================================================================

[TITLE]Northwestern Mutual Wealth Management Co. Has $242,000 Stake in Invesco Biotechnology & Genome ETF $PBE:
[TEXT]
Northwestern Mutual Wealth Management Co. boosted its stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Free Report) by 33.1% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,808 shares of the company’s stock after buying an additional 948 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Invesco Biotechnology & Genome ETF were worth $242,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC lifted its position in Invesco Biotechnology & Genome ETF by 78.1% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 7,242 shares of the company’s stock worth $459,000 after buying an additional 3,176 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Invesco Biotechnology & Genome ETF in the 4th quarter worth approximately $569,000. Janney Montgomery Scott LLC lifted its position in Invesco Biotechnology & Genome ETF by 12.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 5,424 shares of the company’s stock worth $344,000 after buying an additional 604 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Invesco Biotechnology & Genome ETF by 256.8% during the 1st quarter. Farther Finance Advisors LLC now owns 8,616 shares of the company’s stock valued at $535,000 after purchasing an additional 6,201 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Invesco Biotechnology & Genome ETF by 3.2% during the 4th quarter. Bank of America Corp DE now owns 68,973 shares of the company’s stock valued at $4,589,000 after purchasing an additional 2,116 shares in the last quarter.

Get Invesco Biotechnology & Genome ETF alerts:

Invesco Biotechnology & Genome ETF Stock Performance

Invesco Biotechnology & Genome ETF stock opened at $70.59 on Thursday. The company has a market capitalization of $243.54 million, a P/E ratio of 20.44 and a beta of 0.87. The firm’s fifty day simple moving average is $66.44 and its 200-day simple moving average is $64.28. Invesco Biotechnology & Genome ETF has a 1-year low of $54.52 and a 1-year high of $72.84.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.

Read More

Want to see what other hedge funds are holding PBE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Free Report).

Receive News & Ratings for Invesco Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Biotechnology & Genome ETF and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/04/northwestern-mutual-wealth-management-co-has-242000-stake-in-invesco-biotechnology-genome-etf-pbe/


[TITLE]Sana Biotechnology, Inc. $SANA Shares Purchased by Charles Schwab Investment Management Inc.:
[TEXT]
Charles Schwab Investment Management Inc. boosted its position in Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report) by 0.9% in the 1st quarter, Holdings Channel reports. The firm owned 1,066,304 shares of the company’s stock after acquiring an additional 9,792 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Sana Biotechnology were worth $1,791,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Sana Biotechnology by 2.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 280,731 shares of the company’s stock worth $457,000 after buying an additional 6,613 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Sana Biotechnology by 2.1% during the first quarter. Bank of New York Mellon Corp now owns 344,058 shares of the company’s stock worth $578,000 after acquiring an additional 7,230 shares during the last quarter. Rhumbline Advisers grew its stake in Sana Biotechnology by 5.4% during the 1st quarter. Rhumbline Advisers now owns 182,134 shares of the company’s stock valued at $306,000 after acquiring an additional 9,359 shares in the last quarter. ProShare Advisors LLC raised its holdings in Sana Biotechnology by 25.4% in the 4th quarter. ProShare Advisors LLC now owns 47,808 shares of the company’s stock valued at $78,000 after acquiring an additional 9,679 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in Sana Biotechnology by 229.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock valued at $25,000 after acquiring an additional 10,548 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Get Sana Biotechnology alerts:

Sana Biotechnology Trading Up 1.7%

Shares of SANA opened at $3.06 on Monday. The company’s 50-day moving average price is $3.69 and its 200 day moving average price is $2.70. Sana Biotechnology, Inc. has a 12-month low of $1.26 and a 12-month high of $7.30. The firm has a market cap of $727.70 million, a P/E ratio of -2.89 and a beta of 1.88.

Analysts Set New Price Targets

Sana Biotechnology ( NASDAQ:SANA Get Free Report ) last announced its earnings results on Monday, August 11th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. Equities research analysts forecast that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Several research analysts have recently weighed in on SANA shares. JMP Securities restated a “market outperform” rating and set a $5.00 target price on shares of Sana Biotechnology in a report on Tuesday, June 24th. Morgan Stanley assumed coverage on Sana Biotechnology in a research note on Thursday, July 3rd. They set an “overweight” rating and a $12.00 price objective on the stock. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $8.00.

Read Our Latest Report on Sana Biotechnology

Sana Biotechnology Company Profile

(Free Report)

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

Further Reading

Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report).

Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/09/01/sana-biotechnology-inc-sana-shares-purchased-by-charles-schwab-investment-management-inc/

================================================================================

[TITLE]Saudi Arabia Clinical Nutrition Market Analysis Report 2025-2030 | Lifestyle Shifts, Health Consciousness, and Enhanced Healthcare Access Bolster Growth:
[TEXT]
Dublin, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Clinical Nutrition Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to ResearchAndMarkets.com's offering.

The Saudi Arabia Clinical Nutrition Market was valued at USD 0.96 Billion in 2024, and is expected to reach USD 1.53 Billion by 2030, rising at a CAGR of 8.08%

This involves evaluating dietary habits, analyzing biochemical markers, considering medical history, and assessing anthropometric measurements (such as height, weight, and body composition). Based on the nutritional assessment, healthcare professionals, such as registered dietitians or nutritionists, provide personalized dietary counseling.

This includes recommendations for dietary modifications, nutrient supplementation, and lifestyle changes tailored to the individual's specific health needs and goals. Clinical nutrition often involves the application of medical nutrition therapy, which is the use of specific nutrition interventions to treat or manage medical conditions. This may include creating therapeutic diets for conditions such as diabetes, cardiovascular diseases, gastrointestinal disorders, and malnutrition.

Advancements in technology, such as personalized nutrition plans and digital tools for monitoring nutritional intake, can drive innovation and market growth in the clinical nutrition sector. A focus on maternal and child health, along with an emphasis on early childhood nutrition, can drive demand for pediatric clinical nutrition products. Shifts in lifestyle patterns, including dietary habits and a growing interest in fitness and wellness, can contribute to the demand for specialized clinical nutrition products. Increasing disposable income levels in the population can lead to higher spending on healthcare and wellness products, including clinical nutrition. Improvements in healthcare infrastructure, including hospitals and clinics, can enhance access to clinical nutrition products and services.

Key Market Drivers

Technological Innovations

Mobile apps and web platforms designed to monitor and track dietary habits, nutritional intake, and overall health. These platforms may offer personalized recommendations, meal planning, and tools for individuals to manage their nutrition more effectively. Telehealth technologies allow healthcare professionals to remotely monitor patients' nutritional status, provide virtual consultations, and offer dietary guidance. This is especially valuable for patients who may have difficulty accessing in-person care.

Advances in genetics and personalized medicine have led to the emergence of nutrigenomics, which involves studying how an individual's genetic makeup influences their response to nutrients. This can guide personalized dietary recommendations based on genetic factors. Internet of Things (IoT) devices and smart kitchen appliances can assist individuals in preparing and consuming nutritionally balanced meals. These devices may sync with mobile apps to track dietary choices and provide insights into nutritional content.

Wearables, such as fitness trackers and smartwatches, can monitor physical activity, sleep patterns, and sometimes even nutritional intake. This data can be used to assess overall health and tailor dietary recommendations. Artificial Intelligence (AI) and Machine Learning (ML) algorithms are being utilized to analyze vast datasets related to nutrition, metabolism, and health outcomes.

This can lead to more precise personalized nutrition recommendations based on individual health parameters. Integration of nutrition-related information into electronic health records allows for a more comprehensive view of a patient's health history, facilitating better-informed decisions by healthcare professionals. Customized nutritional supplements and enteral feeding solutions can be created using 3D printing technology. This enables healthcare providers to tailor nutritional interventions to specific patient needs.

Virtual Reality (VR) and Augmented Reality (AR) applications are being explored for nutrition education and therapy. These technologies can create immersive experiences to teach patients
[Source link]: https://www.globenewswire.com/news-release/2025/09/04/3144784/28124/en/Saudi-Arabia-Clinical-Nutrition-Market-Analysis-Report-2025-2030-Lifestyle-Shifts-Health-Consciousness-and-Enhanced-Healthcare-Access-Bolster-Growth.html


[TITLE]Questex’s Fierce Pharma, Fierce Biotech and Fierce Healthcare Unveil the 2025 Fierce 50:
[TEXT]
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Questex’s Fierce Pharma, Fierce Biotech and Fierce Healthcare today unveiled the 2025 Fierce 50—a project that highlights the individuals and organizations driving meaningful change across the healthcare, pharma and biotech industries.

The Fierce 50 honors innovators and leaders who are breaking new ground in research, technology, equity and care delivery. From launching first-in-class therapies and advancing AI in clinical workflows to reimagining healthcare access and harnessing data for smarter public health interventions, this year’s honorees are reshaping what’s possible. They’re playing a pivotal role in defining the future of health. The 50 honorees—spanning major pharmaceutical companies, startups, public health leaders and grassroots changemakers—are recognized in one of five categories: Innovation, Social Impact, Breakthrough, Health Equity and Leadership.

Click here to see the 2025 Fierce 50 honorees.

Ayla Ellison, Editor-in-Chief of Fierce Life Sciences and Healthcare, said, "The Fierce 50 of 2025 is
[Source link]: https://www.globenewswire.com/news-release/2025/09/02/3142999/0/en/Questex-s-Fierce-Pharma-Fierce-Biotech-and-Fierce-Healthcare-Unveil-the-2025-Fierce-50.html


[TITLE]University of Hyderabad joins global collaboration to tackle single-use plastics in healthcare:
[TEXT]
The Department of Anthropology at the University of Hyderabad will be participating in an international project aimed at addressing the environmental and health impacts of single-use plastics in healthcare.

The “After the Single Use” project, funded by the Wellcome Trust with a £5.9 million Discovery Award, brings together a global team of researchers from eight countries to explore the cultural, social, and environmental dimensions of medical plastics and promote circular healthcare economies.

Led by Nanda Kishore Kannuri, Associate Professor in the Department of Anthropology, UoH, will receive a grant of £422,608 (approximately ₹5 crore) over a five-year period to contribute to this significant initiative.

The project will examine the historical, local, and global factors that have shaped the current healthcare waste crisis, analyze the life cycles of disposable medical technologies, and collaborate with policymakers, activists, engineers, and designers to develop sustainable solutions.

“This collaboration represents a significant opportunity for the University of Hyderabad to contribute to a global initiative at the intersection of anthropology, environmental sustainability, and healthcare,” Nanda Kishore Kannuri.

“We look forward to working with our international partners to develop innovative solutions that can be applied in diverse healthcare settings,’‘ he added.

The “After the Single Use” project involves a global team of collaborators from the University of Edinburgh (UK), University of New South Wales (Australia), University of Geneva (Switzerland), University of Oslo (Norway), National Institute of Medical Research (Tanzania), CRCF (Senegal), PNG Institute of Medical Research (Papua New Guinea), and Johns Hopkins University (USA), as well as key NGO partners Health Care Without Harm and the Norwegian Bioart Arena.

Published on September 1, 2025
[Source link]: https://www.thehindubusinessline.com/news/education/university-of-hyderabad-joins-global-collaboration-to-tackle-single-use-plastics-in-healthcare/article69999995.ece


[TITLE]The Bull Case For Omega Healthcare Investors (OHI) Could Change Following Q2 Beat and AI Investment News:
[TEXT]
Omega Healthcare Investors recently reported core FFO of $0.77 per share for Q2 2025, exceeding expectations and supporting management's decision to raise full-year guidance after acquiring properties worth US$527 million during the quarter.

The company also invested in MedaSync to help accelerate the use of AI-driven reimbursement solutions in skilled nursing facilities, reflecting a push towards technological innovation in healthcare real estate.

We’ll now examine how Omega’s better-than-expected quarterly results and guidance update may influence the company's investment narrative.

Find companies with promising cash flow potential yet trading below their fair value.

Omega Healthcare Investors Investment Narrative Recap

To own Omega Healthcare Investors, you need to believe in the aging population's ongoing demand for skilled nursing facilities and the company's ability to drive attractive and stable rental income through disciplined acquisitions. While Omega's stronger-than-expected Q2 core FFO and raised 2025 guidance reinforce confidence in its near-term earnings outlook, they do not eliminate the ongoing tenant credit risks from the Genesis bankruptcy, which remains an important short-term catalyst and risk for shareholders.

Of the company's recent announcements, the strategic investment in MedaSync stands out as most relevant to this quarter's results, underscoring Omega's commitment to operational innovation in skilled nursing. This move aligns with the sector's wider reimbursement and efficiency trends and could support rental coverage if AI-powered solutions gain traction, complementing Omega's core growth drivers.

However, investors should also consider that, despite robust quarterly results, challenges related to tenant financial health remain unresolved in the near term, especially as...

Read the full narrative on Omega Healthcare Investors (it's free!)

Omega Healthcare Investors is projected to achieve $1.1 billion in revenue and $603.4 million in earnings by 2028. This outlook assumes a 0.5% annual decline in revenue and an earnings increase of $147.9 million from current earnings of $455.5 million.

Uncover how Omega Healthcare Investors' forecasts yield a $42.57 fair value, in line with its current price.

Exploring Other Perspectives

OHI Community Fair Values as at Aug 2025

Simply Wall St Community members provided three fair value estimates for Omega between US$42.57 and US$71.83 per share. This wide spectrum of opinion meets a market where tenant-specific credit concerns are still top of mind, reminding you to explore several alternative viewpoints.
[Source link]: https://finance.yahoo.com/news/bull-case-omega-healthcare-investors-101204596.html

================================================================================

